the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block

February 14, 2023 updated by: The First Hospital of Qinhuangdao
Dexmedetomidine is an α-2 adrenoreceptor agonist and has been extensively used through intravenous infusion，in order to improved the quality of block in regional anesthesia. In this prospective, randomized study, the authors focus on the effect of dexmedetomidine mixed with ropivacaine in coracoid approach brachial plexus block.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Phase 4

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. American Society of Anesthesiologists (ASA) physical status I or II;
  2. Aged 18-60 years;
  3. The elbow, forearm, wrist or hand surgery

Exclusion Criteria:

  1. History of allergy to local anesthetics;
  2. Coagulation dysfunction, neuromuscular disease or local infection;
  3. The operation time is longer than the local anesthetics effective time.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group Control
40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
Drug: ropivacaine
40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
Experimental: Group Dexmedetomidine
40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
Drug: ropivacaine mixed with dexmedetomidine
40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
duration time
Time Frame: once per hour after surgery until 24 hours after surgery
effective analgesia time
once per hour after surgery until 24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
onset time
Time Frame: 5,10,15,20,25,30 min after injection
5,10,15,20,25,30 min after injection
Visual analogue scale
Time Frame: 2,6,12,24hour after injection
2,6,12,24hour after injection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Hospital of Qinhuangdao

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 12, 2016

Primary Completion (Actual)

March 30, 2017

Study Completion (Actual)

May 25, 2017

Study Registration Dates

First Submitted

October 22, 2016

First Submitted That Met QC Criteria

November 10, 2016

First Posted (Estimate)

November 11, 2016

Study Record Updates

Last Update Posted (Actual)

February 15, 2023

Last Update Submitted That Met QC Criteria

February 14, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dex

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe